ANDA 75959, held by Meitheal. Octreotide Acetate.
As of Nov 16, 2026, ANDA 75959 (Octreotide Acetate), held by Meitheal, was first approved by FDA on Nov 21, 2005, with 7 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Nov 21, 2005 | Original application | Approved | None posted |
| Octreotide AcetateEQ 0.2MG BASE/ML · injectable;injection | Octreotide Acetate | Rx |
| Octreotide AcetateEQ 1MG BASE/ML · injectable;injection | Octreotide Acetate | Rx |
| Aug 8, 2023 | Supplement 33Labeling · Standard review | Approved | None posted |
| Aug 8, 2023 | Supplement 34Labeling · Standard review | Approved | None posted |
| Aug 8, 2023 | Supplement 36Labeling · Standard review | Approved | None posted |
| Nov 4, 2019 | Supplement 29Labeling · Standard review | Approved | None posted |
| Jun 27, 2017 | Supplement 26Labeling · Standard review | Approved | None posted |
| Jul 12, 2012 | Supplement 12Labeling | Approved | None posted |
| Jul 12, 2012 | Supplement 13Labeling · Standard review | Approved | None posted |
| Nov 21, 2005 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters